Isabelle Magalhaes

Associate professor (Docent) in Immunology, Karolinska Institutet.
Since March 2024, Team leader, Karolinska Institutet, Dept. of Medicine Huddinge, Center for Hematology and Regenerative Medicine (HERM).

February 2023-February 2024, Team leader, Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology.
April 2019 - January 2023, Senior researcher, deputy group leader, Karolinska Institutet, Dept. of Oncology Pathology.

April 2015 - March 2019, Assistant professor, Karolinska Institutet, Dept. of  Oncology Pathology.
September 2013 - March 2015, Postdoctoral fellow, U1016 INSERM, Institut  Cochin, Dept. of Endocrinology, Metabolism and Diabetes (Paris, France).
September 2010 - August 2013, Researcher, Karolinska University Hospital Huddinge & Karolinska Institutet, Dept. of Laboratory Medicine.

June 2009 - August 2010, Postdoctoral fellow, Karolinska Institutet, Dept. of Microbiology, Tumor and Cell Biology.
2005-2009, PhD in Immunobiology, Karolinska Institutet, Dept. of Microbiology, Tumor and Cellular Biology.

Thesis title: “/CD8alpha/alpha+ T-cells and Immune Memory/”.

https://openarchive.ki.se/xmlui/bitstream/handle/10616/39450/thesis.pdf?sequence=1&;isAllowed=y
2002, Master in Immunology (Diplôme d’études approfondies), Paris VII University & Institut Pasteur (Paris, France).
2000, Bachelor in Cellular Biology and Physiology, Rennes II University (Rennes, France).

My goal is to contribute to the improvement of chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. Our group is working on the  development of mesothelin (MSLN) CAR T cell therapy for the treatment of ovarian cancer. A preclinical model of orthotopic ovarian cancer in mice has been established in our group, which allows to test /in vivo/ the antitumor efficacy of MSLN CAR T cells.

Recent publications:
Schoutrop E, Poiret T, El-Serafi I, Zhao Y, He R, Moter A, Henriksson J,  Hassan M, Magalhaes I*, Mattsson J*. Tuned activation of MSLN-CAR T cells
induces superior antitumor responses in ovarian cancer models. [1]J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-005691.

Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial
ovarian cancer and its tumor microenvironment. [2]Semin Cancer Biol. 2022 Nov;86(Pt 3):207-223. doi: 10.1016/j.semcancer.2022.03.027.

Schoutrop E, Renken S, Micallef Nilsson I, Hahn P, Poiret T, Kiessling R,  Wickström SL, Mattsson J, Magalhaes I. Trogocytosis and fratricide killing
impede MSLN-directed CAR T cell functionality. [3]Oncoimmunology. 2022;11(1):2093426. doi: 10.1080/2162402X.2022.2093426.

Renken S, Nakajima T, Magalhaes I, Mattsson J, Lundqvist A, Arnér ESJ,  Kiessling R, Wickström SL. Targeting of Nrf2 improves antitumoral responses
by human NK cells, TIL and CAR T cells during oxidative stress. [4]J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004458.

Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I*, Mattsson J*. Mesothelin-Specific CAR T Cells Target Ovarian Cancer. [5]Cancer Res. 2021 Jun 1;81(11):3022-3035. doi: 10.1158/0008-5472.CAN-20-2701.

Magalhaes I, Fernebro J, Abd Own S, Glaessgen D, Corvigno S, Remberger M,  Mattsson J, Dahlstrand H. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor. [6]Adv Ther. 2020 Dec;37(12):5023-5031. doi: 10.1007/s12325-020-01520-w.

[1] https://www.ncbi.nlm.nih.gov/pubmed/36746513/
[2] https://www.ncbi.nlm.nih.gov/pubmed/35395389/
[3] https://www.ncbi.nlm.nih.gov/pubmed/35898704/
[4] https://www.ncbi.nlm.nih.gov/pubmed/35738800/
[5] https://www.ncbi.nlm.nih.gov/pubmed/33795251/
[6] https://www.ncbi.nlm.nih.gov/pubmed/33052561/

I organize since 2016 the /Antigen Presentation and T Cell Activation/ doctoral course (Karolinska Institutet #5739).
https://kiwas.ki.se/katalog/katalog/kurs/9195